XXXX in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.

@entity1 @entity470 @entity19459 @entity1150 @entity38524
UNASSIGNED: Complement inhibitors have not been thoroughly evaluated in the treatment of acute antibody-mediated rejection (ABMR). We performed a prospective, single-arm pilot study to investigate the potential effects and safety of @entity19459 ( @entity38524 ) Berinert added to high-dose intravenous immunoglobulin (IVIG) for the treatment of acute ABMR that is nonresponsive to conventional therapy. Kidney recipients with nonresponsive active ABMR and acute allograft dysfunction were enrolled between April 2013 and July 2014 and received @entity38524 and IVIG for 6 months (six @entity1 ). The primary end point was the change in @entity470 at 6 months after inclusion (M+6). Secondary end points included the changes in histology and DSA characteristics and adverse events as evaluated at M+6. All @entity1 showed an improvement in @entity470 between inclusion and M+6: from 38.7    17.9 to 45.2    21.3 mL/min/1.73 m(2) (p = 0.0277). There was no change in histological features, except a decrease in the C4d deposition rate from 5/6 to 1/6 (p = 0.0455). There was a change in DSA C1q status from 6/6 to 1/6 positive (p = 0.0253). One @entity1150 was observed. In a secondary analysis, C1- @entity19459 @entity1 were compared with a similar historical control group (21 @entity1 ). @entity38524 added to IVIG is safe and may improve allograft function in kidney recipients with nonresponsive acute ABMR.
